PR Newswire All News ReleasesCodex · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 04:15:00·⟳ 抓取 04:17:15 +2m15s·⚡ 决策 08-28 13:49:35 +9h32m·60.3 天前
Pomerantz再次发布ResMed投资者调查广告，核心事实来自已披露的Q4毛利率与Astral安全通知费用
本条是律所投资者调查广告，引用的Astral安全通知费用、Q4毛利率影响和股价下跌均为此前公司披露、SEC文件、FDA更新或更早Pomerantz稿件已出现的事实；没有足以重新定价的新增公司级损害，且缺少可验证实时行情和事件研究支持。
📄 原文PR Newswire All News Releases↗ 原文
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("R…
不做 ResMed Inc.（RMD.US）
不做ResMed Inc.（RMD.US）：本条只是律所调查广告二次扩散，底层Q4毛利率、4200万美元Astral费用和FDA Class I Recall均已较早公开，缺少新增强空催化且未能验证实时行情与event_study。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ResMed确有Astral呼吸机安全通知及约4200万美元费用，FDA也已在2026-07-31将相关问题列为Class I Recall；但2026-08-27的PR Newswire稿主要是Pomerantz律所广告，且同类Pomerantz稿件8月25日已在GlobeNewswire发布，未新增监管处罚、正式集体诉讼进展、费用扩大或经营指引变化，因此对RMD.US不构成新的可交易空头催化。
消息传播链
- FDA更新称ResMed Astral呼吸机问题已被归类为Class I Recall，早于本条律所广告。
- ResMed发布FY2026 Q4业绩，披露收入约15亿美元、GAAP EPS 2.64美元，并在非GAAP调节中列示Astral安全通知费用。
- Pomerantz已发布几乎相同的投资者调查广告，说明8月27日PR Newswire版本不是首次出现。
- 本次抓取信号为Pomerantz通过PR Newswire再次分发投资者调查广告，未见新增金额或监管进展。
关键理由
- 负面经营事实的量级为约4200万美元Astral现场安全通知费用，相对ResMed FY2026全年收入56.53亿美元约0.7%，已在8月初业绩披露中反映。
- 本条律所调查广告本身不等于监管立案、法院认证或新增赔偿责任，短线新增冲击弱于原始召回和业绩披露。
- 8月25日已有几乎相同的Pomerantz稿件，8月27日PR Newswire稿更像二次分发而非新催化。
主要风险
- 若后续出现正式集体诉讼立案、监管处罚、费用显著扩大或公司再次下修指引，RMD.US的负面风险需要重新评估。
- 本次未能调用stock_tools验证最新价格、成交额、案例库和event_study，不能输出可执行做空单。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-06 · 影响 weakens
官方业绩同时显示收入增长9%、非GAAP EPS增长16%，4200万美元费用被列为非GAAP调整项，削弱把律所广告直接升级为空头交易的力度。
检索:ResMed Q4 2026 official results revenue EPS gross margin Astral field safety notification 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-08-25 · 影响 weakens
8月25日已出现相同Pomerantz投资者调查稿，8月27日信号缺少新增事实，削弱新鲜空头edge。
检索:Pomerantz ResMed investor alert August 25 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足使交易从潜在SHORT降级为AVOID；不在缺少行情和样本支持时开空。
方向:未能调用event_study完成合格外部先例定价；从事件性质看，律所调查广告通常需要新增正式法律或监管进展才具备强方向性。
涨幅量级:缺少高相似、同市场、首发锚点干净的样本，不能用先例校准tp/sl。
形态:本条更接近已知负面后的二次律所广告扩散，见光死或无反应风险高，但未用event_study量化。
原文全文
展开原文 · 1,823 字
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether ResMed and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On August 7, 2026, ResMed reported financial results for its fiscal 2026 fourth quarter. Among other items, ResMed reported lower-than-expected adjusted gross margins and operating income. The Company disclosed that it was negatively impacted in the quarter by approximately $42 million worth of field safety notification expenses for its Astral respirators, some of which had a leak issue.
On this news, ResMed's stock price fell $11.30 per share, or 5.06%, to close at $211.94 per share on August 7, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
The investigation concerns whether ResMed and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On August 7, 2026, ResMed reported financial results for its fiscal 2026 fourth quarter. Among other items, ResMed reported lower-than-expected adjusted gross margins and operating income. The Company disclosed that it was negatively impacted in the quarter by approximately $42 million worth of field safety notification expenses for its Astral respirators, some of which had a leak issue.
On this news, ResMed's stock price fell $11.30 per share, or 5.06%, to close at $211.94 per share on August 7, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。